medigraphic.com
Instituto Nacional de Salud Pública

2010, Number 5

<< Back Next >>

salud publica mex 2010; 52 (5)

Toll-like receptors, pathogenesis and immune response to Helicobacter pylori

Sánchez-Zauco NA, Giono-Cerezo S, Maldonado-Bernal C

Language: Spanish
References: 47
Page: 447-454
PDF size: 187.25 Kb.


ABSTRACT

Helicobacter pylori/i> colonize the gastric epithelial, most infected people are asymptomatic, 10 to 20% develop atrophic gastritis, peptic ulcer and less than 3% gastric cancer. These diseases are determined by the relationship between virulence factors of bacteria, host factors such as, genetic predisposition, and immune response. The innate immune response mainly represented by Toll-like receptors and Nod-like receptors that recognize their specific ligands, activate transcription factors as NF-κB, AP-1, CREB-1, inducing production of inflammatory cytokines such as IL -8, IL-12, IL-6, IL-1β, IL-18, TNF-α and IL-10. Chronic inflammation promotes gastric morphological changes, prevents apoptosis and allows angiogenesis generating neoplasic lesions and cancer. The aim of this review is to analyze the mechanisms proposed to date of the innate and adaptative immune response involved in H. pylori infection; remarking the mechanisms related in the elimination or persistence.


REFERENCES

  1. Smith MF, Mitchell A, Li G, Ding S, Fitzmaurice MA, Ryan K, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required of Helicobacter pylori-induced NF-􀁧B activation and chemokine expression by epithelial cells. J Biol Chem 2003;278(35):32552-32560.

  2. Correa P, Piazuelo MB, Camargo MC. Etiopathogenesis of gastric cancer. Scand J Surg 2006;95(4):218-224.

  3. International Agency for Research on Cancer: Schitosomes, liver flukes and Helicobacter pylori. Monographs on the evaluation of carcinogenic risks to humans Lyon: IARC, 1994:61.

  4. Dorer MS, Talarico S, Salama NR. Helicobacter pylori’s unconventional role in health and disease. PLoS Pathog 2009;5(10):1-6.

  5. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296(5566):298-300.

  6. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406(6797):782-787.

  7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801.

  8. Takeda K, Kaisho T, Akira S. Toll like receptors. Annu Rev Immunol 2003; 21:335-376.

  9. Franchi L, McDonald C, Kanneganti TD, Amer A, Núñez G. Nucleotidebinding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol 2006;177:3507-3513.

  10. Sanderson IR, Walker WA. TLRs in the Gut I. The role of TLRs/Nods in intestinal development and homeostasis. Am J Physiol Gastrointest Liver Physiol 2007;292:G6(1)-G10.

  11. Bäckhed F, Rokbi B, Torstensson E, Zhao Y, Nilsson C, Seguin D, et al. Gastric mucosal recognition of Helicobacter pylori is independent of Toll- Like receptor 4. J Infect Dis 2003;187(5):829-836.

  12. Kawahara T, Teshima S, Oka A, Sugiyama T, Kishi K, Rokutan K. TypeI Helicobacter pylori lipopolysaccharide stimulates Toll-Like receptor 4 and activates mitogen oxidase-1 in gastric pit cells. Infect Immun 2001;69:4382-4389.

  13. Hajjar Am, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modification. Nat Immunol 2002;3:354-359.

  14. Moran AP, Lindner B, Walsh EJ. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J Bacteriol 1997;179:6453-6463.

  15. Cunningham MD, Seachord C, Ratcliffe K, Bainbridge B, Aruffo A, Darveau RP. Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Infect Immun 1996;64(9):3601-3608.

  16. Bergman MP, Engering A, Smits HH, van Vliet SJ, van Bodegraven AA,Wirth HP, et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J Exp Med 2004;200(8):979-990.

  17. Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller- Hermelink HK, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004;136(3):521-526.

  18. Pugin J, Schürer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS.Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993;90(7):2744-2748.

  19. Zhao D, Sun T, Zhang X, Guo Y, Yu D, Yang M, et al. Role of CD14 promoter polymorphisms in Helicobacter pylori infection related gastric carcinoma. Clin Cancer Res 2007;13(8):2362-2368.

  20. Zhao Y, Yokota K, Ayada K, Yamamoto Y, Okada T, Shen L, et al. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Tolllike receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human monocytes. J Med Microbi 2007;56(Pt2):154-164.

  21. Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, Logan SM, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci USA 2005;102(26):9247-9252.

  22. Cabral ES, Gelderblom H, Hornung RL, Munson PJ, Martin R, Marques AR. Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis 2006;193(6):849-859.

  23. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175(12):8242-8252.

  24. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Nonsmall cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58(6):1208-1216.

  25. Bauer B, Moese S, Bartfeld S, Meyer TF, Selbach M. Analysis of cell type-specific responses mediated by the type IV secretion system of Helicobacter pylori. Infect Immun 2005;73(8):4643-4652.

  26. Moura SB, Almeida LR, Guerra JB, Rocha GA, Camargos-Rocha AM, Melo FF, et al. Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. Microbes In Infect 2008;10(14-15):1477-1483.

  27. Trejo-de la O A, Torres J, Pérez-Rodríguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008;129(2):333-340.

  28. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008;154(3):360-364.

  29. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of Tolllike receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007;68(11):901-907.

  30. Ng Mt, Van’t Hof R, Crockett JC, Hope ME, Berry S, Thomson J, et al. Increase in NF-{kappa}B binding affinity of the C allelic variant of the Tolllike receptor 9-1237T/C polymorphism is associated with Helicobacter pylori induced gastric disease. Infect Immun 2010;78:1345-1352. DOI:10.1128/IAI.01226-09

  31. Straubinger RK, Greiter A, McDonough PS, Gerold A, Scanziani E, Soldati S, et al. Quantitative evaluation of inflammatory and immune responses in the early stages of chronic Helicobacter pylori infection. Infect Immun 2003;71(5):2693-2703.

  32. Karttunen RA, Karttunen TJ, Yousfi MM, el-Zimaity HM, Graham DY, el-Zaatari FA. Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and mucosa infected with Helicobacter pylori. Scand J Gastroenterol 1997;32(1):22-27.

  33. Agnihotri N, Bhasin DK, Vohra H, Ray P, Singh K, Ganguly NK. Characterization of lymphocytic subset and cytokine production gastric biopsy samples from Helicobacter pylori patients. Scand J Gastroenterol 1998;33(7):704-709.

  34. Noach LA, Bosma NB, Jansen J, Hock FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29(5):425-429.

  35. Bauditz J, Ortner M, Bierbaum M, Niedobitek G, Lochs H, Schreiber S. Production of IL-12 in gastritis relates infection with Helicobacter pylori. Clin Exp Immunol 1999;117(2):316-323.

  36. Zavros Y, Rathinavelu S, Kao JY, Todisco A, Del Valle J, Weinstock JV, et al. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. Proc Natl Acad Sc USA 2003;100(22):12944-12949.

  37. Kido M,Tanaka J,Aoki N, Iwamoto S, Nishiura H, Chiba T, et al. Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cellmediated inflammatory Th2 responses. Infect Immun 2010;78(1):108-114.

  38. Akhiani AA., Schön K, Franzén LE, Pappo J, Lycke N. Helicobacter pylorispecific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004;172(8):5024-5033.

  39. Correia M, Machado JC, Ristimäki A. Basic aspects of gastric cancer. Helicobacter 2009;14 Suppl1:36-40.

  40. Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009;30(2):295-299.

  41. Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, et al. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun 2005;73(5):2999-3006.

  42. Hofman V, Ricci V, Galmiche A, Brest P, Auberger P, Rossi B, et al. Effect of Helicobacter pylori on polymorphonuclear leukocyte migration across polarized T84 epithelial cell monolayers: role of vacuolating toxin VacA and cag pathogenicity island. Infect Immun 2000;68(9):5225-5233.

  43. Peek RM. Events at the host-microbial interface of the gastrointestinal tract IV. The pathogenesis of Helicobacter pylori persistence. AM J Physiol Gastrointest Liver Physiol 2005;289:G8-G12.

  44. D’Elios MM, Bergman MP, Amedei A, Appelmelk BJ, Del Prete G. Helicobacter pylori and gastric autoimmunity. Microbes Infect 2004;6(15):1395-1401.

  45. Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G, et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008;57:1065-1072.

  46. Del Giudice G, Covacci A, Telford J, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001;19:523-563.

  47. Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 2008;44:20-27.




2020     |     www.medigraphic.com